Riskpilot← Back to searchSign inGet full accessR+ Clinical Reinforcement AB
ABActiveOrg 5593793630Observatoriegatan 15Other financial service activities, except insurance and pension funding n.e.c. · NACE 6499Est. 20220 employees
Revenue 2024
SEK 1,1M
-77% vs 2023
EBITDA margin
-8.3%
-142% vs 2023
Equity ratio
14.3%
Financial strength
Net profit 2024
SEK -100K
-156% vs 2023
| Revenue | SEK 1,1M | -77% |
| EBITDA | SEK -95K | -142% |
| Net profit | SEK -100K | -156% |
| Total assets | SEK 944K | +125% |
| Equity | SEK 135K | -42% |
| Employees | 0 | — |
Legal name
R+ Clinical Reinforcement AB
Org number
5593793630
Legal form
Aktiebolag
NACE code
6499 · Other financial service activities, except insurance and pension funding n.e.c.
Founded
6 maj 2022
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Aktiebolaget ska bedriva handel med alla former av fastigheter, värdepapper samt investera i andra aktiebolag. Vidare bedriva medicinsk och akademisk verksamhet i form av konsultationstjänster inkluderande expertstöd inom ledning och organisation.
Address
Observatoriegatan 15
Email
markus.castegren@grundad.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 2 931 | 2 031 | 4 916 | 1 142 |
| Staff expenses | — | −65 | −17 | −0 |
| EBITDA | 543 | — | 225 | −95 |
| Depreciation & amort. | −0 | −0 | — | — |
| EBIT | 543 | 1 814 | 225 | −95 |
| Net financials | — | — | 0 | −5 |
| Profit before tax | 543 | — | 225 | −100 |
| Tax | −112 | 112 | −46 | — |
| Net profit | 431 | 431 | 179 | −100 |
| Item | 2022 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 2 238 | 2 238 | 421 | 944 |
| Equity | 456 | 450 | 235 | 135 |
| Long-term debt | 0 | 0 | — | — |
| Short-term debt | 1 782 | 1 782 | 186 | 809 |
| Total debt | 1 782 | 1 782 | 186 | 809 |
EBITDA margin
-8.3%
This company
15.8%
Market median
-153% vs market
20222024
Equity ratio
14.3%
This company
38.2%
Market median
-63% vs market
20222024
Return on equity
-73.9%
This company
18.4%
Market median
-502% vs market
20222024
Net profit margin
-8.7%
This company
8.1%
Market median
-207% vs market
20222024
Asset turnover
1.21×
This company
1.12×
Market median
+8% vs market
20222024
Debt / equity
5.99×
This company
0.62×
Market median
-866% vs market
20222024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-05-06 – 2022-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-05-01 – 2022-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PK Audit | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2026 | |
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Former (2) | ||
| Deputy Board Member | 2022 – 2024 | |
| Board of Directors | 2024 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of R+ Clinical Reinforcement AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Kennet Rehnqvist | Audit | 0 companies |
| Axel Erik Nyberg | Deputy Board Member | 0 companies |
| Sara Therese Margareta Pallmar | Board of Directors | 0 companies |
| Frida Maria Dunger | Board of Directors | 0 companies |
| Markus Sven-Berto Castegren | Chairman | 0 companies |
| Per Johan Permert | Board of Directors | 0 companies |